Establishment method of fingerprint spectrum of radix astragali and leech kidney-tonifying capsule and component content determination method
Through the combination of ultraviolet light detector and evaporative light detector, the fingerprint and comparison map of Qixie Yishen Capsules were established, which solved the problem of difficult to control the quality of Qixie Yishen Capsules in the existing technology, and achieved efficient and accurate Quality evaluation and chemical composition determination improve the efficiency and accuracy of quality control.
Patent Information
- Application Number
- CN202411058812.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-12-06
AI Technical Summary
The existing technology is difficult to effectively control the quality of Qixi Yishen Capsules, cannot fully reflect the chemical composition characteristics of the drug, and lacks effective quality control methods.
Using a combination of ultraviolet light detector and evaporative light detector, the fingerprint and control fingerprint of Qixi Yishen Capsules were established, and the similarity evaluation software for analysis was used for analysis, and the chemical composition content was determined and peak matching was performed. Hefeng marking achieves quality control.
It has achieved the improvement of the quality evaluation efficiency of Qixi Yishen Capsules, which is simple, accurate, fast analysis speed, strong specialization and operability, and provides a basis for quality control and chemical composition research.
Smart Images

Figure CN119086742A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of traditional Chinese medicine analysis, and in particular to a method for establishing a fingerprint spectrum of Qizhi Yishen Capsule and a method for determining the content of components. Background Art
[0002] Qizhi Yishen capsule (QYC) is composed of ten Chinese medicinal materials, including astragalus, rehmannia, cooked rhubarb, gymnema leaf, fried silkworm, Ligustrum lucidum, leech, Eupolyphaga sinensis, Caulis Sinomenii and Plantago asiatica, which has the effects of nourishing qi and yin, removing blood stasis and unblocking collaterals, and is suitable for diabetic nephropathy with qi and yin deficiency syndrome. The quality standard of QYC mainly uses thin layer chromatography and HPLC-ELSD for qualitative and quantitative detection, but this formula has many medicinal ingredients and complex chemical components. The existing methods cannot effectively reflect the overall chemical composition characteristics of the drug, and there is no report on the quality control of QYC.
[0003] The safety, stability and controllability of the quality of traditional Chinese medicine are the key to the modernization of traditional Chinese medicine. It is urgent to establish an effective method of QYC quality control. When the effective ingredients of traditional Chinese medicine are unclear, the fingerprint of traditional Chinese medicine can combine chromatography, spectroscopy and spectroscopy to more fully reflect the overall distribution of the amount of each chemical component of traditional Chinese medicine, show the relative relationship of the ingredients contained in the medicinal materials, and characteristically identify the authenticity and quality of traditional Chinese medicine. It provides an important basis for comprehensive quality control and in-depth efficacy research. It is an important method of traditional Chinese medicine quality control recognized at home and abroad. Therefore, it is of great significance to establish a QYC fingerprint. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a method for establishing a fingerprint spectrum of Qizhi Yishen Capsule and a method for determining the content of components.
[0005] In order to solve the above problems, the present invention proposes the following technical solutions:
[0006] In a first aspect, the present invention provides a method for establishing a fingerprint spectrum of Qizhi Yishen Capsule, comprising the following steps:
[0007] S1. Prepare the test solution: take a sample with a mass of M1, add a methanol solvent with a volume of V1 to extract, filter, and obtain a test solution, wherein M1:V1=1g:(40-60)mL;
[0008] S2, using an ultraviolet detector (UV) and an evaporative light detector (ELSD) to detect the test solution to obtain a UV chromatogram and an ELSD chromatogram of Qizhi Yishen Capsule;
[0009] The chromatographic conditions include: using a Waters C18 chromatographic column; mobile phase: phase A is methanol, phase B is a formic acid aqueous solution with a volume fraction of 0.1-0.5%; elution conditions are gradient elution according to the volume fraction of 0-5min: 5% phase A, 5-25min: 15% phase A, 25-40min: 31% phase A, 40-60min: 40% phase A, 60-120min: 100% phase A, 120-122min: 5% phase A, 122-130min: 5% phase A; flow rate: 0.8-1.2mL / min; column temperature: 25-35°C; injection volume: 5-15μL; ultraviolet detection wavelength: 250-260nm; evaporative light detector: drift tube temperature 92-97°C; carrier gas flow rate 2.0-3.0L / min;
[0010] S3, analyzing the UV chromatogram and ELSD chromatogram of the Qizhi Yishen Capsule by using a traditional Chinese medicine chromatographic fingerprint similarity evaluation software to obtain a fingerprint of the Qizhi Yishen Capsule; the fingerprint includes a UV chromatogram and an ELSD chromatogram;
[0011] The sample includes the contents of Qizhi Yishen Capsule and the prescription medicinal materials of Qizhi Yishen Capsule.
[0012] Furthermore, in step S1, the extraction is ultrasonic extraction, the extraction power is 300-500W, the frequency is 38-42kHZ, and the extraction time is 20-40min.
[0013] In a second aspect, the present invention provides a method for establishing a control fingerprint of Qizhi Yishen Capsule, the method comprising:
[0014] Take R batches of Qizhi Yishen Capsules, and obtain fingerprints of R batches of Qizhi Yishen Capsules according to the establishment method described in the first aspect; analyze the fingerprints of the R batches of Qizhi Yishen Capsules using Chinese medicine chromatographic fingerprint similarity evaluation software to obtain control fingerprints of Qizhi Yishen Capsules; wherein R≥10; the control fingerprints include UV control chromatograms and ELSD control chromatograms.
[0015] Furthermore, the analysis using the Chinese medicine chromatographic fingerprint similarity evaluation software includes setting the time window width to 0.2-0.3 min and generating a control fingerprint of Qizhi Yishen Capsule as an average.
[0016] Furthermore, it also includes performing common peak matching on the obtained fingerprint spectrum of Qizhi Yishen Capsule to determine the ownership of the common peak:
[0017] Take the prescription medicinal materials of Qizhi Yishen Capsule, and obtain the fingerprint of each medicinal material according to the establishment method described in the first aspect; the prescription medicinal materials are cooked rhubarb, astragalus, plantain seed, Ligustrum lucidum fruit, rehmannia root, clematis, gymnema leaf, leech, fried silkworm and earthworm;
[0018] The sources of the common peaks in the control fingerprint of Qizhi Yishen Capsule were determined according to the retention time and the maximum ultraviolet absorption wavelength.
[0019] Furthermore, the method further includes peak identification of the obtained control fingerprint of Qizhi Yishen Capsule to determine the chemical components corresponding to the peaks:
[0020] Using methanol as solvent, a mixed reference solution with known chemical component concentrations was prepared; the concentrations of the components in the mixed reference solution were as follows:
[0021] The concentration of sinomenine was 540.00-550.00μg / mL, the concentration of 7-O-glucoside of verbascoside was 48.00-52.00μg / mL, the concentration of verbascoside was 58.00-62.00μg / mL, the concentration of terebinthrin was 310.00-315.00μg / mL, the concentration of isoactoside was 415.00-420.00μg / mL, the concentration of aloe-emodin was 20.50-23.00μg / mL, and the concentration of rhubarb was 1. The concentration of chrysophanol was 176.00-181.00 μg / mL, physophanol was 41.00-46.00 μg / mL, gymnema saponin C was 52.00-57.00 μg / mL, oleanolic acid was 55.00-60.00 μg / mL, and ursolic acid was 64.00-70.00 μg / mL;
[0022] The mixed reference solution is subjected to ultraviolet detection and evaporative light detection to obtain a fingerprint of the mixed reference solution; the chromatographic conditions include: using a Waters C18 chromatographic column; mobile phase: phase A is methanol, phase B is a formic acid aqueous solution with a volume fraction of 0.1-0.5%; elution conditions are gradient elution according to the volume fraction of 0-5min: 5% phase A, 5-25min: 15% phase A, 25-40min: 31% phase A, 40-60min: 40% phase A, 60-120min: 100% phase A, 120-122min: 5% phase A, 122-130min: 5% phase A; flow rate: 0.8-1.2mL / min; column temperature: 25-35°C; injection volume: 5-15μL; ultraviolet detection wavelength: 250-260nm; evaporative light detector: drift tube temperature 92-97°C; carrier gas flow rate 2.0-3.0L / min;
[0023] The peaks of the fingerprint of the Qizhi Yishen Capsule are marked according to the fingerprint of the reference solution to determine the chemical components corresponding to the peaks.
[0024] Furthermore, the concentration of each component in the mixed reference solution is as follows:
[0025] The concentration of sinomenine was 547.00μg / mL, the concentration of verbascoside was 50.30μg / mL, the concentration of verbascoside was 60.60μg / mL, the concentration of teruncoside was 313.00μg / mL, the concentration of isoactoside was 418.00μg / mL, the concentration of aloe-emodin was 20.20μg / mL, the concentration of rhein was 67.00μg / mL, the concentration of rhein was 21.20μg / mL, the concentration of chrysophanol was 179.20μg / mL, the concentration of physaccharin methyl ether was 44.80μg / mL, the concentration of gymnema saponin C was 55.00μg / mL, the concentration of oleanolic acid was 58.00μg / mL, and the concentration of ursolic acid was 66.00μg / mL.
[0026] In a third aspect, the present invention provides a control fingerprint of Qizhi Yishen Capsule obtained by the method established according to the second aspect of the present invention, wherein the control fingerprint includes a UV control chromatogram and an ELSD control chromatogram.
[0027] In a fourth aspect, the present invention provides a quality control method for Qizhi Yishen Capsules, characterized in that the method comprises:
[0028] A1. Take the content of the Qizhi Yishen Capsule to be tested, and obtain the fingerprint of the Qizhi Yishen Capsule to be tested according to the establishment method described in the first aspect;
[0029] A2. Evaluate the similarity between the fingerprint obtained in step A1 and the reference fingerprint obtained by the establishment method described in the second aspect. If the similarity between the UV chromatogram and the ELSD chromatogram in the fingerprint and the reference fingerprint is ≥0.70, the quality of the Qizhi Yishen Capsule to be tested is determined to be qualified.
[0030] In a fifth aspect, the present invention provides a method for determining the content of chemical components in Qizhi Yishen Capsules, wherein the content of chemical components in Qizhi Yishen Capsules is determined by using an ultraviolet detector and an evaporative light detector, wherein the chemical components include: sinomenine, verbascoside-7-O-glucoside, verbascoside, teruncifolioside, isoacteoside, aloe-emodin, rhein, rhein, chrysophanol, physcion methyl ether, gymnema saponin C, oleanolic acid and ursolic acid;
[0031] The method comprises:
[0032] (1) Establish standard curves for each chemical component:
[0033] Using methanol as solvent, 7-13 mixed reference solutions containing different known concentrations of various chemical components were prepared; among them, the concentration of sinomenine was 20.00-600.00 μg / mL, the concentration of verbascoside was 1.00-70.00 μg / mL, the concentration of gentianin was 10.00-380.00 μg / mL, the concentration of isoactoside was 10.00-500.00 μg / mL, and the concentration of aloe-emodin was 10.00-500.00 μg / mL. The concentration is 0.50-40.00μg / mL, the concentration of rhein is 1.00-80.00μg / mL, the concentration of rhein is 0.50-30.00μg / mL, the concentration of chrysophanol is 5.00-200.00μg / mL, the concentration of physophanol is 1.0-50.00μg / mL, the concentration of gymnema saponin C is 1.00-60.00μg / mL, the concentration of oleanolic acid is 1.00-60.00μg / mL, and the concentration of ursolic acid is 1..00-70.00μg / mL;
[0034] Under the same chromatographic conditions, each mixed reference solution is injected into an ultraviolet detector and an evaporative light detector respectively, and the chromatographic peak of each chemical component is determined according to the retention time of each chemical component, and the chromatographic peak area of each chemical component is obtained; wherein the chromatographic conditions include: using Waters C18 chromatographic column; mobile phase: methanol for phase A, gradient elution for phase B with a volume fraction of 0-5min: 5% phase A, 5-25min: 15% phase A, 25-40min: 31% phase A, 40-60min: 40% phase A, 60-120min: 100% phase A, 120-122min: 5% phase A, 122-130min: 5% phase A; flow rate: 0.8-1.2mL / min; column temperature: 25-35℃; injection volume: 5-15μL; UV detection wavelength: 250-260nm; evaporative light detector: drift tube temperature 92-97℃; carrier gas flow rate 2.0-3.0L / min;
[0035] The standard curves of the chemical components were established by taking the peak area of the chromatographic peak of each chemical component as the ordinate and the concentration of each chemical component as the abscissa;
[0036] (2) Obtaining the chromatographic peak area of each chemical component in the Qizhi Yishen Capsule to be tested:
[0037] Take the content of the Qizhi Yishen Capsule to be tested with a mass of M1, extract it with a volume of V1 of methanol solvent, filter it, and obtain a test solution; wherein M1:V1=1g:(40-60)mL;
[0038] Under the same chromatographic conditions as step (1), the test solution is injected into an ultraviolet detector and an evaporative light detector respectively to obtain a chromatogram of the Qizhi Yishen Capsule to be tested, and the chromatographic peaks of each chemical component are determined according to the retention time of each chemical component, and the chromatographic peak area of each chemical component is obtained;
[0039] (3) Determine the content of each chemical component in the Qizhi Yishen Capsule to be tested:
[0040] According to the established standard curves of various chemical components, the concentrations of various chemical components were obtained from the chromatographic peak areas of various chemical components in the tested Qizhi Yishen Capsules, and the contents of various chemical components in the tested Qizhi Yishen Capsules were calculated.
[0041] Furthermore, in the step (1), methanol is used as a solvent to prepare 7-10 mixed reference solutions containing different known concentrations of various chemical components; wherein the components of the mixed reference solution are: sinomenine concentration is 30.00-547.00 μg / mL, verbascoside concentration is 3.00-50.30 μg / mL, verbascoside concentration is 3.00-60.60 μg / mL, and terebinthrin concentration is 19.0 0-313.00μg / mL, the concentration of isoacteoside was 26.00-418.00μg / mL, the concentration of aloe-emodin was 1.10-20.20μg / mL, the concentration of rhein was 4.00-67.00μg / mL, the concentration of rhein was 1.20-21.20μg / mL, the concentration of chrysophanol was 11.00-179.20μg / mL, and the concentration of physophanol methyl ether was 2.50-44.80μg / mL.
[0042] Compared with the prior art, the technical effects achieved by the present invention include:
[0043] The present invention provides a method for establishing a fingerprint of Qizhi Yishen Capsule. For the first time, a method of connecting an ultraviolet detector in series with an evaporative light detector is used to simultaneously establish two fingerprints of the Chinese patent medicine Qizhi Yishen Capsule. Under the same chromatographic conditions, qualitative identification of two fingerprints and content determination of at least 10 components can be performed simultaneously, thereby improving the quality evaluation efficiency of the medicine. The present invention combines ultraviolet detection (UV) and evaporative light detection (ELSD), and by reasonably selecting chromatographic conditions and the preparation of control sample concentrations, the establishment, peak attribution and peak identification of the fingerprint of Qizhi Yishen Capsule are achieved, and the method has the advantages of simplicity, high accuracy, fast analysis speed, strong specificity and strong operability, so that it can be used for the quality control of Qizhi Yishen Capsule, and also provides a basis for further studying the chemical composition and quality standards of Qizhi Yishen Capsule.
[0044] The present application also provides a method for establishing a control fingerprint of Qizhi Yishen Capsule and its use in quality control. The present application further provides a method for determining the content of chemical components in Qizhi Yishen Capsule, using the same chromatographic conditions as those in the method for establishing the fingerprint of Qizhi Yishen Capsule to achieve the determination of the content of at least 10 chemical components in Qizhi Yishen Capsule. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying any creative work.
[0046] Figure 1 HPLC-UV fingerprints of 19 batches of QYC samples;
[0047] Figure 2 HPLC-ELSD fingerprints of 19 batches of QYC samples;
[0048] Figure 3 HPLC-UV reference spectrum established from 19 batches of QYC samples;
[0049] Figure 4 HPLC-ELSD reference spectrum established from 19 batches of QYC samples;
[0050] Figure 5 HPLC-UV spectra of the reference substance, QYC samples and their prescription medicinal materials;
[0051] Figure 6 HPLC-ELSD spectra of the reference substance, QYC samples and their prescription medicinal materials;
[0052] Figure 7 HPLC-UV graph and UV absorption spectrum of characteristic peak (A) in QYC sample;
[0053] Figure 8 HPLC-UV graph and UV absorption spectrum of characteristic peak (B) in the prescription medicinal material;
[0054] Fig. 9 HPLC-UV images of blank solvent (A), mixed reference substance (B) and QYC test substance (C);
[0055] Fig.10 This is a box plot of the contents of 10 ingredients in Qizhi Yishen Capsule. DETAILED DESCRIPTION
[0056] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments. Obviously, the embodiments described below are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0057] It should be understood that when used in this specification and the appended claims, the terms "include" and "comprises" indicate the presence of described features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or combinations thereof.
[0058] It should also be understood that the terms used in this description of the embodiments of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the embodiments of the present invention. As used in the description of the embodiments of the present invention and the appended claims, unless the context clearly indicates otherwise, the singular forms of "a", "an" and "the" are intended to include plural forms.
[0059] 1. Instruments and Materials
[0060] 1.1 Instruments and equipment
[0061] High performance liquid chromatograph, ultraviolet detector, evaporative light detector.
[0062] 1.2 Sample
[0063] The sample information of Qizhi Yishen Capsule used in the examples of the present invention is shown in Table 1-1.
[0064] Table 1-1 Qizhi Yishen Capsule Sample Information
[0065]
[0066]
[0067] The prescription medicinal material information of Qizhi Yishen Capsule used in the embodiment of the present invention is shown in Table 1-2.
[0068] Table 1-2 Prescription information of Qizhi Yishen Capsules
[0069]
[0070] 2 Experimental methods
[0071] 2.1 Establishment of fingerprint
[0072] 2.1.1 Chromatographic conditions
[0073] A Waters C18 chromatographic column (250 mm × 4.6 mm, 5 μm) was used for separation; the mobile phase was methanol (A)-0.2% formic acid aqueous solution (B), and the gradient elution conditions were shown in Tables 1-3; the flow rate was 1.0 mL / min, the column temperature was 30°C, and the injection volume was 10 μL; the ultraviolet detection wavelength was 254 nm; the evaporative light detector: the drift tube temperature was 95°C; and the carrier gas flow rate was 2.5 L / min.
[0074] Table 1-3 Mobile phase gradient elution conditions
[0075]
[0076] 2.1.2 Preparation of reference solution
[0077] Take appropriate amount of sinomenine, verbascoside-7-O-glucoside, verbascoside, privet glycoside, isophylloside, aloe-emodin, rhein, rhein, chrysophanol, physophanol methyl ether, gymnema saponin C, oleanolic acid and ursolic acid reference substances, accurately weigh them, add methanol to dissolve, and prepare them to sinomenine concentration of 547.00 μg / mL, verbascoside concentration of 50.30 μg / mL, verbascoside concentration of 60.60 μg / mL, privet glycoside concentration of 313.0 0μg / mL, isoacteoside concentration of 418.00μg / mL, aloe-emodin concentration of 20.20μg / mL, rhein concentration of 67.00μg / mL, rhein concentration of 21.20μg / mL, chrysophanol concentration of 179.20μg / mL, physophanol methyl ether concentration of 44.80μg / mL, gymnema saponin C concentration of 55.00μg / mL, oleanolic acid concentration of 58.00μg / mL, ursolic acid concentration of 66.00μg / mL. Take appropriate amounts of each reference solution and mix them to obtain a mixed reference solution.
[0078] 2.1.3 Preparation of test solution
[0079] Take about 0.5 g of the contents of QYC (or single prescription medicinal material powder), accurately weigh it, place it in a stoppered conical flask, add 25 mL of methanol, weigh it, extract it by ultrasound (power 400 W, frequency 40 kHz) for 30 min, take it out, cool it, weigh it and make up the lost weight with methanol, shake it well, filter it (0.22 μm), and take the filtrate to obtain it.
[0080] Example 1
[0081] This embodiment provides a method for establishing a fingerprint spectrum of Qizhi Yishen Capsule, comprising the following steps:
[0082] S1. Prepare the test solution according to "2.1.3";
[0083] S2. Using an ultraviolet detector and an evaporative light detector to sample and detect the test solution under the chromatographic conditions of item "2.1.1", detect the test solution, and obtain a UV chromatogram and an ELSD chromatogram of Qizhi Yishen Capsule;
[0084] S3. The above results are exported into ".cdf" format and peak matching is performed in the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (2012.130723 Version)" software to obtain the fingerprint of Qizhi Yishen Capsule.
[0085] Methodological investigation of the fingerprint establishment method provided in Example 1
[0086] (1) Precision test
[0087] Take the same test solution (QYC-19) and continuously sample and detect 6 times under the chromatographic conditions of item "2.1.1". Record the chromatograms under ultraviolet detector (UV) and evaporative light detector (ELSD) respectively. Export the results in ".cdf" format and perform peak matching in the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (2012.130723 Version)" software. Take peak 23 (UV) and peak 13 (ELSD) as reference peaks, respectively, and calculate the relative retention time and relative peak area ratio of other common peaks.
[0088] (2) Repeatability test
[0089] Take the same batch of test samples (QYC-19) and prepare 6 test sample solutions in parallel according to the method in "2.1.3". Samples were injected and tested under the chromatographic conditions in "2.1.1". The chromatograms were recorded under ultraviolet detector (UV) and evaporative light detector (ELSD). The results were exported in ".cdf" format and peak matching was performed in the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (2012.130723 Version)" software. Peak 23 (UV) and peak 13 (ELSD) were used as reference peaks, and the relative retention time and relative peak area ratio of other common peaks were calculated.
[0090] (3) Stability test
[0091] Take the same batch of test solution (QYC-19) and perform sampling and detection under the chromatographic conditions of "2.1.1" at 0, 2, 4, 8, 12, and 24 h. Record the chromatograms under ultraviolet detector (UV) and evaporative light detector (ELSD), respectively. Export the results in ".cdf" format and perform peak matching in the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (2012.130723 Version)" software. Take peak 23 (UV) and peak 13 (ELSD) as reference peaks, respectively, and calculate the relative retention time and relative peak area ratio of other common peaks.
[0092] The results are shown in Tables 1-4 and 1-5. The precision results show that the relative retention time of each common peak is ≤3%, and the relative peak area RSD value is ≤5%, indicating that the instrument and method have good precision; the repeatability results show that the relative retention time of each common peak is ≤3%, and the relative peak area RSD value is ≤5%, indicating that the method has good repeatability; the stability results show that the relative retention time of each common peak is ≤3%, and the relative peak area RSD value is ≤6%, indicating that the test solution has good stability within 24 hours.
[0093] Table 1-4 Results of methodological investigation of HPLC-UV fingerprint
[0094]
[0095] Table 1-5 Methodological investigation results of HPLC-ELSD fingerprint
[0096]
[0097]
[0098] Example 2
[0099] This embodiment provides a method for establishing a control fingerprint of Qizhi Yishen Capsule, the method comprising:
[0100] 19 batches of Qizhi Yishen Capsule contents were taken, and fingerprints of 19 batches of Qizhi Yishen Capsule were obtained respectively according to the establishment method described in Example 1; the fingerprints of the 19 batches of Qizhi Yishen Capsule contents were analyzed using Chinese medicine chromatographic fingerprint similarity evaluation software to obtain a control fingerprint of Qizhi Yishen Capsule.
[0101] In this example, the data of the fingerprints of 19 batches of Qizhi Yishen Capsules in ".cdf" format were imported into the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (2012.130723 Version)" software, and the QYC-1 test sample spectrum was used as the reference spectrum. The time window width was set to 0.3min, and the reference spectrum was generated by the average. The reference spectrum was used for fingerprint peak matching and similarity evaluation.
[0102] The peak identification and attribution were established as follows:
[0103] Take one batch of QYC capsules and one batch each of the prescription medicinal materials Rheum officinale (RRR), Astragalus (AR), Plantago (PS), Ligustrum lucidum (LLF), Rehmannia root (RR), Caulis Sinomenii (SC), Gymnema sylvestre leaves (FG), Leech (H), Bombyx batryticatus (BB), and Eupolyphaga sinensis (ES), and prepare the test solution according to the method under "2.1.3". Take the reference solution under "2.1.2" separately. The above QYC test solution, prescription medicinal material test solution and reference solution are tested under the chromatographic conditions under "2.1.1". Record the chromatograms under ultraviolet detector (UV) and evaporative light detector (ELSD), respectively. Determine the origin of the common peaks in QYC according to the retention time and the maximum ultraviolet absorption wavelength, and mark the peaks according to the chromatographic peaks of the reference.
[0104] HPLC-UV chromatograms and UV absorption spectra of characteristic peaks in QYC samples (A) and characteristic peaks in prescription medicinal materials (B) are shown in Figure 7-Figure 8 , peak matching results are shown in Figure 1 and Figure 2 , peak identification results are shown in Figure 5 and Figure 6 The generated control map is shown in Figure 3 and Figure 4 .
[0105] The UV chromatogram successfully matched 35 common peaks, and the ELSD chromatogram successfully matched 29 common peaks. The similarity results of each batch of samples and the reference spectrum are shown in Table 2-1. In the UV spectrum, except for QYC-17 with a similarity value of 0.793, the rest are greater than 0.800, indicating that the generated reference spectrum is well representative; in the ELSD spectrum, except for QYC-15 and QYC-17 with similarity values of 0.737 and 0.717, the rest are greater than 0.800, indicating that the generated reference spectrum is well representative.
[0106] Table 2-1 Similarity evaluation of QYC samples and reference spectra
[0107]
[0108] In the UV chromatogram ( Figure 5), there are 26 common peaks (peaks 5, 6, 7, 8, 9, 11, 12, 13, 14, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35) that can be attributed to the prescription medicinal materials. By comparing with the spectrum of the reference substance, a total of 12 common peaks were identified, peaks 5, 6, and 7 were sinomenine, peak 20 was calycosin-7-O-glucoside, peak 21 was calycoside, peak 23 was terebinurin, peak 24 was isoactoside, peak 31 was aloe-emodin, peak 32 was rhein, peak 33 was emodin, peak 34 was chrysophanol, and peak 35 was physophanol methyl ether. Among them, peaks 5, 6, 7, 8, 11, 12, 13, 14, 17, and 25 were attributed to Caulis Sinomenii, peaks 9, 21, and 24 were attributed to Plantago seed, peaks 18 and 26 were attributed to Gymnema sylvestris leaves, peaks 19, 21, 23, and 27 were attributed to Ligustrum lucidum fruit, peak 20 was attributed to Astragalus membranaceus, and peaks 28, 29, 31, 32, 33, 34, and 35 were attributed to Rhubarb.
[0109] In the ELSD chromatogram ( Figure 6 ), there are 14 common peaks (peaks 1, 2, 3, 4, 5, 8, 11, 13, 16, 20, 21, 22, 23, 24) that can be attributed to the prescription medicinal materials. Since there is no UV absorption information of the compound in the spectrum collected by ELSD, the chromatographic peaks can only be inferred based on the retention time. By comparing with the spectrum of the reference substance, a total of 4 common peaks were identified, peaks 1, 2, and 3 are sinomenine, peak 13 is terunculoside, peak 22 is oleanolic acid, and peak 23 is ursolic acid. Combined with the results marked in the UV spectrum, the peaks with clear sources are as follows: peaks 1, 2, 3, and 11 are attributed to Caulis Adenophorae, peak 4 is attributed to Rehmannia glutinosa, peaks 5 and 8 are attributed to Rheum officinale, and peaks 13, 16, 22, and 23 are attributed to Fructus Ligustri Lucidi; based on the retention time comparison, the possible peak attributions are inferred as follows: there is a chromatographic peak with the same retention time at peak 20 in the spectrum of Fructus Ligustri Lucidi and Astragalus, there is a chromatographic peak with the same retention time at peak 21 in the spectrum of Leech, Bombyx Batryticatus, Gymnema Sylvestre leaves, Caulis Adenophorae and Plantago, and there is a chromatographic peak with the same retention time at peak 24 in the spectrum of Eupolyphaga sinensis, Leech, Bombyx Batryticatus, Gymnema Sylvestre leaves, Caulis Adenophorae and Plantago.
[0110] Example 3
[0111] The embodiment of the present invention provides a quality control method for Qizhi Yishen Capsule, the method comprising:
[0112] A1. Take the content of the Qizhi Yishen Capsule to be tested, and obtain the fingerprint of the Qizhi Yishen Capsule to be tested according to the establishment method described in Example 1;
[0113] A2. Evaluate the similarity between the fingerprint obtained in step A1 and the control fingerprint obtained by the establishment method described in Example 2. If the similarity between the UV chromatogram and the ELSD chromatogram in the fingerprint and the control fingerprint is ≥0.70, the quality of the Qizhi Yishen Capsule to be tested is determined to be qualified.
[0114] It can be seen from the results in Table 2-1 that the control fingerprint established according to Example 2 can quickly determine whether the quality of Qizhi Yishen Capsules is qualified.
[0115] Example 4
[0116] The embodiment of the present invention provides a method for determining the content of chemical components in Qizhi Yishen Capsule, and specifically provides a method for determining the content of multiple chemical components in Qizhi Yishen Capsule.
[0117] 4.1 Chromatographic conditions
[0118] The chromatographic conditions of this example are the same as those in item "2.1.1".
[0119] 4.2 Preparation of reference solution:
[0120] Take appropriate amount of sinomenine, verbascoside, verbascoside, ligustrin, isophylloside, aloe-emodin, rhein, rhein, chrysophanol and physophanol methyl ether reference substances, weigh accurately, add methanol to dissolve, and make up to volume to obtain the reference substance mother solution; take appropriate amount of each reference substance mother solution, mix, make up to volume, and perform gradient dilution to obtain mixed reference substance solutions of different concentrations, see Table 4-1.
[0121] Table 4-1 Gradient concentration of each reference solution
[0122]
[0123] 4.3 Preparation of test solution: The preparation of the test solution in this example is the same as that in item "2.1.3".
[0124] Now, the method provided in this embodiment is investigated by methodology.
[0125] (1) Specificity and system suitability test
[0126] Inject blank solvent, mixed reference solution and QYC test solution under the chromatographic conditions of "4.1" and record the chromatogram and calculate the separation degree and theoretical plate number of each component to be tested.
[0127] The chromatograms of blank solvent, mixed reference solution and QYC test solution are shown in Fig. 9 The separation degree of each component was greater than 1.5, and the number of theoretical plates was above 20 000, indicating that the established chromatographic conditions had good specificity and strong system adaptability.
[0128] (2) Linearity and range
[0129] Take each reference solution under "4.2" and dilute them in sequence to obtain reference solutions of different concentrations. Take the above reference solutions and inject them under the chromatographic conditions of "4.1" to calculate the peak area. Take the peak area (Y) of each reference solution as the ordinate and the concentration as the abscissa (X, μg / mL), make a scatter plot and perform linear fitting, calculate the regression equation and correlation coefficient (r). The results are shown in Table 4-2.
[0130] (3) Limit of detection and limit of quantification
[0131] Take the No. 5 concentration mixed standard solution in Table 4-1, continuously dilute and inject for testing, and examine the detection limit when the signal-to-noise ratio is 3 and the quantification limit when the signal-to-noise ratio is 10. The results are shown in Table 4-2.
[0132] Table 4-2 Linearity, range, limit of quantification and limit of detection of each compound
[0133]
[0134] (4) Precision test
[0135] Take the same mixed reference solution and inject it continuously for 6 times according to the chromatographic conditions in "4.1", record the peak area of each component and calculate the RSD value.
[0136] (5) Repeatability test
[0137] Take the same batch of samples (QYC-19) and prepare 6 test solutions in parallel according to the method in "4.3". Inject and test under the chromatographic conditions in "4.1", record the peak area of each component and calculate the RSD value.
[0138] (6) Stability test
[0139] Take the mixed reference solution and test solution, and perform sampling and detection under the chromatographic conditions under "2.2.1" at 0, 4, 8, 12, 16, 20, and 24 hours respectively, record the peak area of each component, and calculate the RSD value.
[0140] The results of the above precision, repeatability and stability tests are shown in Table 4-3. The results show that the precision, repeatability and stability of this method are good.
[0141] Table 4-3 Precision, repeatability and stability test results
[0142]
[0143] (7) Sample recovery test
[0144] Take 6 portions of samples of the same batch (QYC-19) with known content, each portion is about 0.25g, accurately weighed, and accurately added with sinomenine, verbascoside, verbascoside, privet glycoside, isoacteroside, aloe-emodin, rhein, rhein, chrysophanol and physophanol methyl ether reference substances in a ratio of 1:1 to the content of each component in the sample. Prepare the test solution according to the method under "4.3", and perform sampling and detection according to the chromatographic conditions under "4.1". Calculate the average recovery rate and RSD value of each component.
[0145] The results are shown in Table 4-4. The sample recovery rate of each component meets the relevant requirements of General Chapter 9101, Part 4 of the 2020 "Chinese Pharmacopoeia", indicating that this method has high accuracy.
[0146] Table 4-4 Sample recovery test results
[0147]
[0148]
[0149] The method of Example 4 was used to determine the contents of 10 components in 19 batches of samples.
[0150] Take different batches of QYC samples and prepare the test solution according to the method in "4.3". Inject and test according to the chromatographic conditions in "4.1". Record the peak area of each component and use it in the regression equation to calculate the content of each component.
[0151] The statistical results of the contents of the 10 ingredients are shown in Fig.10The content of sinomenine in 19 batches of QYC samples was 9.516-16.527 mg / g, with an average of 14.507 mg / g; the content of 7-O-glucoside was 0.485-0.811 mg / g, with an average of 0.688 mg / g; the content of verbascoside was 0.853-1.750 mg / g, with an average of 1.210 mg / g; the content of terepristin glycoside was 11.037-17.834 mg / g, with an average of 13.714 mg / g; the content of isophylloside was 1.575-11.522 mg / g, The average value is 8.721 mg / g; the aloe-emodin content is 0.342-0.664 mg / g, with an average value of 0.536 mg / g; the rhein content is 0.729-0.962 mg / g, with an average value of 0.824 mg / g; the rhein content is 0.579-0.318 mg / g, with an average value of 0.446 mg / g; the chrysophanol content is 0.835-1.391 mg / g, with an average value of 1.135 mg / g; the physophanol content is 0.424-0.727 mg / g, with an average value of 0.540 mg / g. Except for the abnormally low content of isoactoside in one batch (QYC-19), there were no abnormal values in the content of each detected component in other batches of samples, indicating that the quality of samples between different production batches is stable; and the production batch number of QYC-19 is "3021078" (produced in 2021), which may be affected by storage conditions and cause changes in composition. Overall, the content of sinomenine, terepristin glycosides and isoactoside in the samples is significantly higher than that of the other 7 components, which is the material basis that needs to be focused on.
[0152] In the above embodiments, the description of each embodiment has its own emphasis. For parts that are not described in detail in a certain embodiment, reference can be made to the relevant descriptions of other embodiments.
[0153] The above is a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can easily think of various equivalent modifications or replacements within the technical scope disclosed by the present invention, and these modifications or replacements should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.
Claims
1. A method for establishing a fingerprint of Qizhi Yishen Capsule, characterized in that: The following steps are involved: S1. Prepare the test solution: take a sample with a mass of M1, add a methanol solvent with a volume of V1 to extract, filter, and obtain a test solution, wherein M1:V1=1g:(40-60)mL; S2. Using an ultraviolet detector and an evaporative light detector to detect the test solution, and obtaining a UV chromatogram and an ELSD chromatogram of Qizhi Yishen Capsule; The chromatographic conditions include: using a Waters C18 chromatographic column; mobile phase: phase A is methanol, phase B is a formic acid aqueous solution with a volume fraction of 0.1-0.5%; elution conditions are gradient elution according to the volume fraction of 0-5min: 5% phase A, 5-25min: 15% phase A, 25-40min: 31% phase A, 40-60min: 40% phase A, 60-120min: 100% phase A, 120-122min: 5% phase A, 122-130min: 5% phase A; flow rate: 0.8-1.2mL / min; column temperature: 25-35°C; injection volume: 5-15μL; ultraviolet detection wavelength: 250-260nm; evaporative light detector: drift tube temperature 92-97°C; carrier gas flow rate 2.0-3.0L / min; S3, analyzing the UV chromatogram and ELSD chromatogram of the Qizhi Yishen Capsule by using a traditional Chinese medicine chromatographic fingerprint similarity evaluation software to obtain a fingerprint of the Qizhi Yishen Capsule; the fingerprint includes a UV chromatogram and an ELSD chromatogram; The sample includes the contents of Qizhi Yishen Capsule and the prescription medicinal materials of Qizhi Yishen Capsule.
2. The method of establishing as claimed in claim 1, characterized in that: In step S1, the extraction is ultrasonic extraction, the extraction power is 300-500W, the frequency is 38-42kHZ, and the extraction time is 20-40min.
3. A method for establishing a control fingerprint of Qizhi Yishen Capsule, characterized in that: The method comprises: Take R batches of Qizhi Yishen Capsules, and obtain fingerprints of R batches of Qizhi Yishen Capsules according to the establishment method described in any one of claims 1-2; analyze the fingerprints of the R batches of Qizhi Yishen Capsules using Chinese medicine chromatographic fingerprint similarity evaluation software to obtain a control fingerprint of Qizhi Yishen Capsules; wherein R≥10; the control fingerprint includes a UV control chromatogram and an ELSD control chromatogram.
4. The establishment method according to claim 3, characterized in that: The analysis using the traditional Chinese medicine chromatographic fingerprint similarity evaluation software includes setting the time window width to 0.2-0.3 min and generating a control fingerprint of Qizhi Yishen Capsule by averaging.
5. The establishment method according to claim 3, characterized in that: The method also includes performing common peak matching on the obtained fingerprint spectrum of Qizhi Yishen Capsule to determine the attribution of the common peaks: Take the prescription medicinal materials of Qizhi Yishen Capsule, and obtain the fingerprint of each medicinal material according to the establishment method described in any one of claims 1-2; the prescription medicinal materials are cooked rhubarb, astragalus, plantain seed, Ligustrum lucidum fruit, rehmannia root, clematis, gymnema leaf, leech, fried silkworm and earthworm; The sources of the common peaks in the control fingerprint of Qizhi Yishen Capsule were determined according to the retention time and the maximum ultraviolet absorption wavelength.
6. The method of establishing as claimed in claim 3, characterized in that: The method also includes peak identification of the obtained control fingerprint of Qizhi Yishen Capsule to determine the chemical components corresponding to the peaks: Using methanol as solvent, a mixed reference solution with known chemical component concentrations was prepared; the concentrations of the components in the mixed reference solution were as follows: The concentration of sinomenine was 540.00-550.00μg / mL, the concentration of 7-O-glucoside of verbascoside was 48.00-52.00μg / mL, the concentration of verbascoside was 58.00-62.00μg / mL, the concentration of terebinthrin was 310.00-315.00μg / mL, the concentration of isoactoside was 415.00-420.00μg / mL, the concentration of aloe-emodin was 20.50-23.00μg / mL, and the concentration of rhubarb was 1. The concentration of chrysophanol was 176.00-181.00 μg / mL, physophanol was 41.00-46.00 μg / mL, gymnema saponin C was 52.00-57.00 μg / mL, oleanolic acid was 55.00-60.00 μg / mL, and ursolic acid was 64.00-70.00 μg / mL; The mixed reference solution is subjected to ultraviolet light detection and evaporative light detection to obtain a fingerprint of the mixed reference solution; the chromatographic conditions include: using a Waters C18 chromatographic column; Mobile phase: Phase A is methanol, and phase B is gradient elution with a volume fraction of 0-5min: 5% phase A, 5-25min: 15% phase A, 25-40min: 31% phase A, 40-60min: 40% phase A, 60-120min: 100% phase A, 120-122min: 5% phase A, 122-130min: 5% phase A; flow rate: 0.8-1.2mL / min; column temperature: 25-35℃; injection volume: 5-15μL; UV detection wavelength: 250-260nm; evaporative light detector: drift tube temperature 92-97℃; carrier gas flow rate 2.0-3.0L / min; The peaks of the fingerprint of the Qizhi Yishen Capsule are marked according to the fingerprint of the reference solution to determine the chemical components corresponding to the peaks.
7. The method of establishing as claimed in claim 6, characterized in that: The concentrations of the components in the mixed reference solution are as follows: The concentration of sinomenine was 547.00μg / mL, the concentration of verbascoside was 50.30μg / mL, the concentration of verbascoside was 60.60μg / mL, the concentration of teruncoside was 313.00μg / mL, the concentration of isoactoside was 418.00μg / mL, the concentration of aloe-emodin was 20.20μg / mL, the concentration of rhein was 67.00μg / mL, the concentration of rhein was 21.20μg / mL, the concentration of chrysophanol was 179.20μg / mL, the concentration of physaccharin methyl ether was 44.80μg / mL, the concentration of gymnema saponin C was 55.00μg / mL, the concentration of oleanolic acid was 58.00μg / mL, and the concentration of ursolic acid was 66.00μg / mL.
8. A quality control method for Qizhi Yishen Capsules, characterized in that: The method comprises: A1. Take the content of the Qizhi Yishen Capsule to be tested, and obtain the fingerprint of the Qizhi Yishen Capsule to be tested according to the method established in any one of claims 1-2; A2. Evaluate the similarity between the fingerprint obtained in step A1 and the control fingerprint obtained by the establishment method according to any one of claims 3 to 7. If the similarity between the UV chromatogram and the ELSD chromatogram in the fingerprint and the control fingerprint is ≥ 0.70, the quality of the Qizhi Yishen Capsule to be tested is determined to be qualified.
9. A method for determining the content of chemical components in Qizhi Yishen Capsule, characterized in that: The contents of chemical components in Qizhi Yishen Capsule were determined by using ultraviolet detector and evaporative light detector, and the chemical components included sinomenine, verbascoside-7-O-glucoside, verbascoside, terebinthiol, isoacteoside, aloe-emodin, rhein, rhein, chrysophanol, physcion methyl ether, gymnema saponin C, oleanolic acid and ursolic acid. The method comprises: (1) Establish standard curves for each chemical component: Using methanol as solvent, 7-13 mixed reference solutions containing different known concentrations of various chemical components were prepared; among them, the concentration of sinomenine was 20.00-600.00 μg / mL, the concentration of verbascoside was 1.00-70.00 μg / mL, the concentration of gentianin was 10.00-380.00 μg / mL, the concentration of isophylloside was 10.00-500.00 μg / mL, and the concentration of aloe rhubarb was 10.00-500.00 μg / mL. The concentration of rhein is 0.50-40.00μg / mL, the concentration of rhein is 1.00-80.00μg / mL, the concentration of rhein is 0.50-30.00μg / mL, the concentration of chrysophanol is 5.00-200.00μg / mL, the concentration of physophanol is 1.0-50.00μg / mL, the concentration of gymnema saponin C is 1.00-60.00μg / mL, the concentration of oleanolic acid is 1.00-60.00μg / mL, and the concentration of ursolic acid is 1.00-70.00μg / mL; Under the same chromatographic conditions, each mixed reference solution is injected into an ultraviolet detector and an evaporative light detector respectively, and the chromatographic peak of each chemical component is determined according to the retention time of each chemical component, and the chromatographic peak area of each chemical component is obtained; wherein the chromatographic conditions include: using Waters C18 chromatographic column; mobile phase: phase A is methanol, phase B is a formic acid aqueous solution with a volume fraction of 0.1-0.5%; elution conditions are as follows: 0-5min: 5% phase A, 5-25min: 15% phase A, 25-40min: 31% phase A, 40-60min: 40% phase A, 60-120min: 100% phase A, 120-122min: 5% phase A, 122-130min: 5% phase A gradient elution; flow rate: 0.8-1.2mL / min; column temperature: 25-35℃; injection volume: 5-15μL; UV detection wavelength: 250-260nm; evaporative light detector: drift tube temperature 92-97℃; carrier gas flow rate 2.0-3.0L / min; The standard curves of the chemical components were established by taking the peak area of the chromatographic peak of each chemical component as the ordinate and the concentration of each chemical component as the abscissa; (2) Obtaining the chromatographic peak area of each chemical component in the Qizhi Yishen Capsule to be tested: Take the content of the Qizhi Yishen Capsule to be tested with a mass of M1, extract it with a volume of V1 of methanol solvent, filter it, and obtain a test solution; wherein M1:V1=1g:(40-60)mL; Under the same chromatographic conditions as step (1), the test solution is injected into an ultraviolet detector and an evaporative light detector respectively to obtain a chromatogram of the Qizhi Yishen Capsule to be tested, and the chromatographic peaks of each chemical component are determined according to the retention time of each chemical component, and the chromatographic peak area of each chemical component is obtained; (3) Determine the content of each chemical component in the Qizhi Yishen Capsule to be tested: According to the established standard curves of various chemical components, the concentrations of various chemical components were obtained from the chromatographic peak areas of various chemical components in the tested Qizhi Yishen Capsules, and the contents of various chemical components in the tested Qizhi Yishen Capsules were calculated.
10. The method for determining the content of chemical components in Qizhi Yishen Capsule according to claim 9, characterized in that: In the step (1), methanol is used as a solvent to prepare 7-10 mixed reference solutions containing different known concentrations of various chemical components; wherein the concentration of sinomenine is 30.00-547.00 μg / mL, the concentration of verbascoside is 3.00-50.30 μg / mL, the concentration of verbascoside is 3.00-60.60 μg / mL, and the concentration of terebinthrin is 19.00-313.00 μg / mL. μg / mL, the concentration of isoacteoside was 26.00-418.00μg / mL, the concentration of aloe-emodin was 1.10-20.20μg / mL, the concentration of rhein was 4.00-67.00μg / mL, the concentration of rhein was 1.20-21.20μg / mL, the concentration of chrysophanol was 11.00-179.20μg / mL, and the concentration of physophanol methyl ether was 2.50-44.80μg / mL.
Citation Information
Patent Citations
UPLC-UV (Ultra Performance Liquid Chromatography-Ultraviolet) contrast fingerprint spectrum of astragalus and leech capsules as well as establishment method and application
CN114839301A
Construction method of fingerprint spectrum of radix astragali and leech collateral dredging formula and quality evaluation method of capsule
CN116930341A
